x Brown

Cicor reports strong year-to-date sales growth of 25%, outlook remains positive

Cicor continues to pursue its strategy of accelerated growth through both acquisitions and organic growth. The recently announced strategic partnership with the French Clayens Group has the potential to generate additional business for Cicor for smart drug delivery devices and other medical and industrial applications.

Based on the positive Q3 revenue and order intake progression, Cicor reconfirms its 2023 guidance to achieve annual sales of CHF 380 to 410 million and an operating result at EBITDA level of CHF 40 to 45 millions

TrustedParts x A

About The Author